⌘K
Loading ticker…
As of 2026-08-24, Viridian Therapeutics, Inc. Common Stock (VRDN) has a 3-month relative strength percentile of 91 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 54. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.6%, relative volume 0.62×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
VRDN is in a stage 1 base, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 20.7% / 0.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
VRDN is held by 21 ETFs as of May 2026. Top owner: VTWO at 0.04% weight, $7M notional. Top 3 carry $18M.
Held by 65 ETFs · $238M across latest filings · largest weight 2.23% (LFSC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.04% | $7M | −0.03 pp |
| SCHASchwab U.S. Small-Cap ETF | 0.03% | $7M | −0.03 pp |
| VHTVanguard Health Care ETF | 0.02% | $3M | −0.01 pp |
| VFMO | 0.16% | $3M | +0.11 pp |
| LFSC | 2.23% | $2M | new |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.06% |
| $1M |
| −0.06 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $854K | — |
| ESML | 0.03% | $710K | −0.02 pp |
| FMED | 1.34% | $548K | new |
| ONEQ | 0.00% | $533K | — |
Showing 10 of 21 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VRDN Jan avg: 5.14% median: 3.57% win: 75% σ: 15.20% n: 4 2022-04-12 → 2026-07-31 | VRDN Feb avg: -10.98% median: -10.63% win: 0% σ: 6.98% n: 4 2022-04-12 → 2026-07-31 | VRDN Mar avg: -18.85% median: -17.77% win: 0% σ: 11.71% n: 4 2022-04-12 → 2026-07-31 | VRDN Apr avg: -13.45% median: -22.61% win: 40% σ: 17.79% n: 5 2022-04-12 → 2026-07-31 | VRDN May avg: -0.55% median: -9.88% win: 40% σ: 18.71% n: 5 2022-04-12 → 2026-07-31 | VRDN Jun avg: 1.65% median: 0.43% win: 60% σ: 5.25% n: 5 2022-04-12 → 2026-07-31 | VRDN Jul avg: 10.22% median: 14.43% win: 80% σ: 20.34% n: 5 2022-04-12 → 2026-07-31 | VRDN Aug avg: 14.16% median: 0.88% win: 50% σ: 36.46% n: 4 2022-04-12 → 2026-07-31 (current) | VRDN Sep avg: 12.29% median: 4.88% win: 50% σ: 31.74% n: 4 2022-04-12 → 2026-07-31 | VRDN Oct avg: -4.29% median: -4.08% win: 25% σ: 11.47% n: 4 2022-04-12 → 2026-07-31 | VRDN Nov avg: 24.02% median: 30.45% win: 75% σ: 16.48% n: 4 2022-04-12 → 2026-07-31 | VRDN Dec avg: 8.01% median: 6.48% win: 50% σ: 18.46% n: 4 2022-04-12 → 2026-07-31 |